OR WAIT 15 SECS
The merger enhances STA’s end-to-end capabilities as a full-service contract development and manufacturing organization.
STA Pharmaceutical announced on July 31, 2017 that it has merged with WuXi AppTec’s Pharmaceutical Development Services (PDS) division. The PDS division offers pre-formulation development, formulation development, as well as clinical trial material (CTM) manufacturing, packaging, and labeling of oral solid dosage forms. The portfolio also includes various enabling technology platforms for poorly soluble drugs such as spray dried dispersion, hot melt extrusion, micro- or nanosuspension, and liquid-filled hard-gelatin capsules.
Following the merger, STA Pharmaceutical will provide fully integrated small-molecule API and drug product solutions to global clients. The merger enables STA to advance new chemical entities from pre-clinical stage to new drug application (NDA) and to market faster and more efficiently for pharma and biotech customers.
This development enhances STA’s end-to-end capabilities as a full-service contract development and manufacturing organization (CDMO). STA anticipates rapid growth in clinical trial supply, especially for early stage compounds.
Two commercial-scale drug product manufacturing facilities are currently under construction, one of which is expected to become operational later in 2017 and the other early next year in 2018.
Source: WuXi AppTec